Get the Stockscreener App
4.21
4.30%
-0.20
Foghorn Therapeutics Inc stock is traded at $4.21, with a volume of 174.61K.
It is down -4.30% in the last 24 hours and down -9.05% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.41
Open:
$4.4
24h Volume:
174.61K
Relative Volume:
1.12
Market Cap:
$237.99M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.7991
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+2.43%
1M Performance:
-9.05%
6M Performance:
-0.46%
1Y Performance:
-49.15%
1-Day Range:
$4.05
$4.49
1-Week Range:
$4.03
$4.69
52-Week Range:
$2.9448
$9.70
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.21 | 249.30M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.99 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.60 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.15 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.38 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.77 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Identifying reversal signals in Foghorn Therapeutics Inc.2025 Market Overview & Fast Moving Stock Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsBull Run & Free Weekly Watchlist of Top Performers - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsPrice Action & AI Driven Stock Movement Reports - newser.com
Foghorn Therapeutics to engage investors at oncology conferences - Traders Union
Foghorn Therapeutics Inc. to Participate in Major Healthcare Conferences in November 2025 - Quiver Quantitative
Foghorn Therapeutics (NASDAQ: FHTX) plans three investor events; webcasts for 90 days - Stock Titan
Is Foghorn Therapeutics Inc. stock bottoming outAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Applying big data sentiment scoring on Foghorn Therapeutics Inc.Short Setup & Real-Time Market Trend Scan - newser.com
Published on: 2025-11-03 02:03:18 - newser.com
Why Foghorn Therapeutics Inc. stock could outperform in 2025Market Growth Report & Low Volatility Stock Recommendations - newser.com
Will Foghorn Therapeutics Inc. continue its uptrendWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
How moving averages guide Foghorn Therapeutics Inc. tradingMarket Growth Report & Weekly Top Gainers Trade List - newser.com
Can swing trading help recover from Foghorn Therapeutics Inc. lossesJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Published on: 2025-11-02 02:35:38 - newser.com
Can trapped investors hope for a rebound in Foghorn Therapeutics Inc.Market Performance Report & Verified Stock Trade Ideas - newser.com
Why Foghorn Therapeutics Inc. is moving todayPortfolio Value Report & Weekly Hot Stock Watchlists - newser.com
Published on: 2025-11-01 05:22:36 - newser.com
What does recent volatility data suggest for Foghorn Therapeutics Inc.Watch List & Free Verified High Yield Trade Plans - newser.com
Foghorn Therapeutics shares progress on three protein degrader programs - BioWorld MedTech
Has Foghorn Therapeutics Inc. formed a bullish divergencePortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
Foghorn Therapeutics advances ARID1B, CBP, EP300 development - Traders Union
Foghorn Therapeutics Announces Key Pipeline Updates - TipRanks
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs - The Manila Times
Foghorn Therapeutics Updates on Selective Degrader Programs and Virtual Investor Event Announcement - Quiver Quantitative
Foghorn Therapeutics Inc Announces Pipeline Updates for Degrader Programs - TradingView
Foghorn (Nasdaq: FHTX) updates degraders: ARID1B tied to 5% of solid tumors; CBP IND 2026 - Stock Titan
Momentum divergence signals in Foghorn Therapeutics Inc. chartQuarterly Portfolio Report & AI Forecast for Swing Trade Picks - newser.com
How risky is Foghorn Therapeutics Inc. stock nowEarnings Growth Report & Consistent Profit Trading Strategies - newser.com
Volatility clustering patterns for Foghorn Therapeutics Inc.Quarterly Market Review & Long Hold Capital Preservation Plans - newser.com
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):